Sign in
Active, not recruitingNo phase

Acute Effects of a Urate-lowering Bacterial Therapeutic on Small Intestinal Transcriptomics and Glycomics in Healthy Subjects

Key facts

Who runs it
Örebro University, Sweden
Where
Sweden1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
8 people, planned
Started
9 Apr 2026
Expected to end
Jun 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • BEO001 Probiotic
  • BEO001 Probiotic + Beta-Glucan
  • Placebo
Record updated
20 October 2026

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Signed informed consent
  • Age 18-60 years
  • BMI 18.5 - 29.9 kg/m²
  • Willing to avoid probiotics, fermented foods, and maintain stable diet/lifestyle for the study duration

Who cannot take part

  • Regular use of NSAIDs, antibiotics, steroids, immunomodulators
  • Use of recreational drugs, tobacco, or nicotine
  • Use of probiotics or antibiotics within 4 weeks prior
  • Chronic GI, inflammatory, metabolic (including renal), or significant psychiatric disease
  • Acute infection/allergy within 2 weeks
  • Known allergy to local anesthetics or sedatives for gastroscopy
  • Bleeding disorder or use of anticoagulants
  • Any condition deemed by investigator to compromise safety or data integrity
  • Alcohol >9 units/week
  • Pregnancy, breastfeeding, or planning pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a pilot study investigating how a novel probiotic supplement (BEO001), with and without a dietary fiber (beta-glucan), affects the lining of the small intestine in healthy people. The main goal is to see if a single dose of the probiotic changes gene activity (transcriptomics) and sugar molecule patterns (glycomics) in the gut. Eight participants will take three different treatments (placebo, probiotic alone, probiotic with fiber) in a random order, with at least 10 days between each. A gastroscopy to collect small intestinal tissue samples (biopsies) is performed the morning after each treatment. Blood and breath samples are also collected at these visits to explore effects on metabolism and inflammation. To understand how different sampling methods compare, participants collect stool samples and simple rectal swabs at home before any treatment. Researchers analyze the sugar molecules and bacteria in these samples, then compare them to each other and to the gut tissue samples collected after treatment. This helps determine if easier-to-collect samples can provide similar information to gut biopsies. The study also aims to combine all data (including genetics and diet) to identify key targets for future research and to attempt to grow 'mini-gut' organoids from the biopsies. The results will help design larger future studies in people with high uric acid levels.

The 3 groups in the trial

  • Probiotic (BEO001)Existing treatment, for comparison

    Participants receive the BEO001 probiotic powder, which contains two probiotic strains

    Treatment: BEO001 Probiotic

  • Synbiotic (BEO001 + Beta-Glucan)Existing treatment, for comparison

    Participants receive the BEO001 probiotic powder plus beta-glucan fiber powder.

    Treatment: BEO001 Probiotic + Beta-Glucan

  • PlaceboPlacebo, for comparison

    Participants receive placebo powder.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Acute Effects of a Urate-lowering Probiotic Food Supplement/Bacterial Therapeutic on Small Intestinal Transcriptomics and Glycomics in Healthy Subjects
Record updated
20 October 2026